Phenethyl isothiocyanate inhibits proliferation and induces apoptosis in pancreatic cancer cells in vitro and in a MIAPaca2 xenograft animal model

Nutrition and Cancer

Volumn 66, Issue 4, 2014, Pages 747-755

  Stan, Silvia D ^a   Singh, Shivendra V ^b   Whitcomb, David C ^b   Brand, Randall E ^b  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PHENETHYL ISOTHIOCYANATE; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; ISOTHIOCYANIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; DNA FRAGMENTATION; DOWN REGULATION; DRUG EFFICACY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA FRAGMENTATION; HUMANS; ISOTHIOCYANATES; MALE; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899952561     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.795979     Document Type: Article

References (49)

1. Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, et al.: Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66, 95-106, 2006.
2. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, and Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20, 1218-1249, 2006.
3. MaitraA, Fukushima N, TakaoriK, and Hruban RH: Precursors to invasive pancreatic cancer. Adv Anat Pathol 12, 81-91, 2005.
4. Siegel R, Naishadham D, and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62, 10-29, 2012.
5. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al.: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117, 2010.
6. Stan SD, Singh SV, and Brand RE: Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol 7, 347-356, 2010.
7. Olsen GW, Mandel JS, Gibson1 RW,Wattenberg LW, and Schuman LM: A case-control study of pancreatic cancer and cigarettes, alcohol, coffee, and diet. Am J Public Health 79, 1016-1019, 1989.
8. Verhoeven DT, Goldbohm RA, van Poppel G, Verhagen H, and van den Brandt PA: Epidemiological studies on Brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev 5, 733-748, 1996.
9. Chan JM,Wang F, and Holly EA:Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco bay area. Cancer Epidemiol Biomarkers Prev 14, 2093-2097, 2005.
10. Higdon JV, Delage B,Williams DE, and Dashwood RH: Cruciferous vegetables and human cancer risk: epidemiological evidence and mechanistic basis. Pharmacol Res 5, 224-236, 2007.
11. Silverman DT, Swanson CA, Gridley G, Wacholder S, Greenberg RS, et al.: Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst 90, 1710-1719, 1998.
12. Larsson SC, Hakansson N, Naslund I, Bergkvist L, and Wolk A: Fruit and vegetable consumption in relation to pancreatic cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 15, 301-305, 2006.
13. Hecht SS: Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev 32, 395-411, 2000.
14. Hayes JD, Kelleher MO, and Eggleston IM: The cancer chemopreventive actions of phytochemicals derived from glucosinolates. Eur J Nutr 47(Suppl 2), 73-88, 2008.
15. Powolny AA, Bommareddy A, Hahm ER, Normolle DP, Beumer JH, et al.:Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer. J Natl Cancer Inst 103, 571-584, 2011.
16. Cheung KL and Kong AN: Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J 12, 87-97, 2010.
17. Zhang Y: Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. Mutat Res 555, 173-190, 2004.
18. Stan SD, Kar S, Stoner GD, and Singh SV: Bioactive food components and cancer risk reduction. J Cell Biochem 104, 339-356, 2008.
19. Xiao D, Powolny AA, Moura MB, Kelley EE, Bommareddy A, et al.: Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem 285, 26558-26569, 2010.
20. Bommareddy A, Hahm ER, Xiao D, Powolny AA, Fisher AL, et al.: Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res 69, 3704-3712, 2009.
21. clinicaltrials.gov Identifiers: NCT00968461, NCT00005883, and NCT0069 1132. Retrieved from www.clinicaltrials.gov
22. Nishikawa A, Furukawa F, Uneyama C, Ikezaki S, Tanakamaru, et al.: Chemopreventive effects of phenethyl isothiocyanate on lung and pancreatic tumorigenesis in N-nitrosobis(2-oxopropyl)amine-treated hamsters. Carcinogenesis 17, 1381-1384, 1996.
23. Stan SD, Zeng Y, and Singh SV: Ayurvedic medicine constituent withaferin A causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr Cancer 60(S1), 51-60, 2008.
24. Hendzel MJ,Wei Y, ManciniMA,VanHooser A, Ranalli T, et al.:Mitosisspecific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106, 348-360, 1997.
25. Artavanis-Tsakonas S, Rand MD, and Lake RJ: Notch signaling: cell fate control and signal integration in development. Science 284, 770-776, 1999.
26. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, et al.: Notch mediates TGF α-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3, 565-576, 2003.
27. Mysliwiec P and Boucher MJ: Targeting Notch signaling in pancreatic cancer patients-rationale for new therapy. Adv Med Sci 54, 136-142, 2009.
28. Miyamoto Y, Hosotani R, Wada M, Lee JU, Koshiba T, et al.: Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology 56, 73-82, 1999.
29. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, et al.: Bcl- XL protects pancreatic adenocarcinoma cells against CD95-and TRAILreceptor- mediated apoptosis. Oncogene 19, 5477-5486, 2000.
30. Friess H, Lu Z, Andren-Sandberg A, Berberat P, Zimmermann A, et al.: Moderate activation of the apoptosis inhibitor Bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg 228, 780-787, 1998.
31. Gross A, McDonnell JM, and Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13, 1899-1911, 1999.
32. Cain K, Brown DG, Langlais C, and Cohen GM: Caspase activation involves the formation of the aposome, a large (approximately 700 kDa) caspase-activating complex. J Biol Chem 274, 22686-22692, 1999.
33. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, et al.: Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavablemutant.JBiolChem273, 33533-33539, 1998.
34. Go MJ, Eastman DS, and Artavanis-Tsakonas S: Cell proliferation control by Notch signaling in Drosophila development. Development 125, 2031-2040, 1998.
35. Shelly LL, Fuchs C, and Miele L: Notch-1 inhibits apoptosis in murine erythroleukemia cells and is necessary for differentiation induced by hybrid polar compounds. J Cell Biochem 73, 164-175, 1999.
36. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, et al.: Rational targeting of Notch in cancer. Oncogene 27, 5124-5131, 2008.
37. Ferrara C, Tessari G, Poletti A, Giacon C, Meggiato T, et al.: Ki-67 and c-jun expression in pancreatic cancer: a prognostic marker? Oncol Rep 6, 1117-1122, 1999.
38. Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, et al.: Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg 186, 486-492, 2003.
39. Lebe B, Sagol O, Ulukus C, Coker A, Karademir S, et al.: The importance of cyclin D1 and Ki-67 expression on the biological behavior of pancreatic adenocarcinomas. Pathol Res Pract 200, 389-396, 2004.
40. Karamitopoulou E, Zlobec I, Tornillo L, Carafa V, Schaffner T, et al.: Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). Pathology 42, 229-234, 2010.
41. Aloysius MM, Hewavisenthi SJ, Bates TE, Rowlands BJ, Lobo DN, et al.: Predictive value of tumor proliferation indices in periampullary cancers: Ki-67, mitotic activity index (MI) and volume corrected mitotic index (M/V) using tissue microarrays. World J Surg 34, 2115-2121, 2010.
42. Dang CX, Han Y, Qin ZY, and Wang YJ: Clinical significance of expression of p21 and p53 proteins and proliferating cell nuclear antigen in pancreatic cancer. Hepatobiliary Pancreat Dis Int 1, 302-305, 2002.
43. Ji Y, Kuo Y, and Morris ME: Pharmacokinetics of dietary phenethyl isothiocyanate in rats. Pharm Res 22, 1658-1666, 2005.
44. Zhang Y and Talalay P: Mechanism of differential potencies of isothiocyanates as inducers of anticarcinogenic Phase 2 enzymes. Cancer Res 58, 4632-4639, 1998.
45. Konsue N, Kirkpatrick J, Kuhnert N, King LJ, Ioannides C: Repeated oral administration modulates the pharmacokinetic behavior of the chemopreventive agent phenethyl isothiocyanate in rats. Mol Nutr Food Res 54, 426-432, 2010.
46. Ji Y and MorrisME: Determination of phenethyl isothiocyanate in human plasma and urine by ammonia derivatization and liquid chromatographytandem mass spectrometry. Anal Biochem 323, 39-47, 2003.
47. Liebes L, Conaway CC, Hochster H, Mendoza S, Hecht SS, et al.: Highperformance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. Anal Biochem 291, 279-289, 2001.
48. Wang X, Govind S, Sajankila SP, Mi L, Roy R, et al.: Phenethyl isothiocyanate sensitizes human cervical cancer cells to apoptosis induced by cisplatin. Mol Nutr Food Res 55, 1572-1581, 2011.
49. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, et al.: Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 10, 241-252, 2006.